P1103: INMIND: A PHASE 3 STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB VERSUS PLACEBO PLUS LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL). (23rd June 2022)

Record Type:
Journal Article
Title:
P1103: INMIND: A PHASE 3 STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB VERSUS PLACEBO PLUS LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL). (23rd June 2022)
Main Title:
P1103: INMIND: A PHASE 3 STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB VERSUS PLACEBO PLUS LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL)
Authors:
Sehn, L. H.
Hübel, K.
Luminari, S.
Salar, A.
Wahlin, B. E.
Gopal, A. K.
Bonnet, C.
Paneesha, S.
Trneny, M.
Mashegu, H.
Lihou, C.
Li, D.
Scholz, C. W.
Abstract:
Is Part Of:
HemaSphere. Volume 6(2022)Supplement 3
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Issue Display:
Volume 6, Issue 3 (2022)
Year:
2022
Volume:
6
Issue:
3
Issue Sort Value:
2022-0006-0003-0000
Page Start:
993
Page End:
994
Publication Date:
2022-06-23
Subjects:
Hematology -- Periodicals
616.15005
Journal URLs:
https://journals.lww.com/hemasphere/pages/default.aspx ↗
http://journals.lww.com/pages/default.aspx ↗
DOI:
10.1097/01.HS9.0000847280.69256.81 ↗
Languages:
English
ISSNs:
2572-9241
Deposit Type:
Legaldeposit
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:
22735.xml